Cargando…

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study

BACKGROUND AND AIMS: The ProCID study evaluated the efficacy and safety of three doses of a 10% liquid intravenous immunoglobulin (IVIg) preparation (panzyga(®)) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). This report describes the safety findings. METHODS: Patients we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cornblath, David R., van Doorn, Pieter A., Hartung, Hans-Peter, Merkies, Ingemar S. J., Katzberg, Hans D., Hinterberger, Doris, Clodi, Elisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442284/ https://www.ncbi.nlm.nih.gov/pubmed/37378806 http://dx.doi.org/10.1007/s40264-023-01326-z

Ejemplares similares

A randomised, multi‐centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol
por: Cornblath, David R., et al.
Publicado: (2018)

Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy
por: Cornblath, David R, et al.
Publicado: (2022)

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019)

Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Merkies, Ingemar S. J., et al.
Publicado: (2022)

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial
por: van Schaik, Ivo N., et al.
Publicado: (2016)

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
por: Tortorici, Michael A., et al.
Publicado: (2021)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
por: Talaei, M., et al.
Publicado: (2021)

Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review
por: Lewis, Richard A., et al.
Publicado: (2020)

Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
por: Adrichem, Max E., et al.
Publicado: (2022)

Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins
por: Mahdi-Rogers, Mohamed, et al.
Publicado: (2010)

Electrophysiological Responsiveness to Long-Term Therapy in Chronic Inflammatory Demyelinating Polyneuropathy: Case Report
por: Khomand, Payam, et al.
Publicado: (2020)

Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes
por: Breiner, Ari, et al.
Publicado: (2019)

Diphtheritic Inflammation of Procident Uterus and Vagina
por: Duncan, J. Matthews
Publicado: (1862)

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Khoo, Anthony, et al.
Publicado: (2019)

The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies
por: Querol, Luis A., et al.
Publicado: (2022)

The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes – An Observational Study
por: Dunnigan, Samantha K., et al.
Publicado: (2014)

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study
por: van Schaik, Ivo N., et al.
Publicado: (2019)

Comparison of diabetes patients with “demyelinating” diabetic sensorimotor polyneuropathy to those diagnosed with CIDP
por: Dunnigan, Samantha K, et al.
Publicado: (2013)

Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post‐hoc analysis of the immunoglobulin overtreatment in CIDP trial
por: van Veen, Robin, et al.
Publicado: (2022)

Temporal Dispersion and Duration of the Distal Compound Muscle Action Potential Do Not Distinguish Diabetic Sensorimotor Polyneuropathy From Chronic Inflammatory Demyelinating Polyneuropathy
por: Alcantara, Monica, et al.
Publicado: (2022)

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy
por: Kuitwaard, K., et al.
Publicado: (2020)

Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy
por: Stettner, Mark, et al.
Publicado: (2015)

A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
por: Mallick, Rajiv, et al.
Publicado: (2023)

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
por: Blackhouse, Gord, et al.
Publicado: (2010)

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US
por: Guptill, Jeffrey T, et al.
Publicado: (2019)

Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy
por: Kuitwaard, Krista, et al.
Publicado: (2021)

Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy
por: Markvardsen, Lars K., et al.
Publicado: (2023)

Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective
por: Cocito, Dario, et al.
Publicado: (2023)

Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins
por: Ritter, Christian, et al.
Publicado: (2015)

Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy
por: Seino, Yusuke, et al.
Publicado: (2018)

Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale
por: Barnett, Carolina, et al.
Publicado: (2015)

Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy
por: Graf, Jonas, et al.
Publicado: (2018)

Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study
por: Adrichem, M. E., et al.
Publicado: (2019)

Subcutaneous Immunoglobulin in Infantile Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report
por: Cianci, Paola, et al.
Publicado: (2019)

Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial
por: Kuwabara, Satoshi, et al.
Publicado: (2017)

Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
por: Klehmet, Juliane, et al.
Publicado: (2023)

Chronic Inflammatory Demyelinating Polyneuropathy Variant with Creatine-Kinase Elevation and Vanishing Effect of Immunoglobulins
por: Finsterer, Josef, et al.
Publicado: (2017)

High-dose immunoglobulin-dependent chronic demyelinating inflammatory polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis
por: Hiya, Satomi, et al.
Publicado: (2022)

Depression with Chronic Inflammatory Demyelinating Polyneuropathy
por: Marwale, Arun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kj6gc0g9hlck6tk1mope9889sg